MorphoSys's Licensee Janssen Announces Topline Phase 3 Results for Guselkumab TremfyaR in Adults with Active Psoriatic Arthritis news with additional features

DGAPNews MorphoSys AG Key words Study14.06.2019 1358 The issuer is solely responsible for the content of this announcement.PlaneggMunich Germany June 14 2019MorphoSys's Licensee Janssen Announces Topline Phase 3 Results for Guselkumab TremfyaR in Adults ...